European venture firms have traditionally treated deeptech as a distinct asset class demanding long‑horizon capital. In the first half of 2026, however, a wave of Tier‑1 investors — including Atomico, HV Capital, Lakestar and Creandum — deployed funds into 13 nascent deeptech companies spanning quantum computing, synthetic biology, advanced materials and next‑gen AI hardware. The deals range from seed rounds of €1‑2 million to Series A tranches exceeding €10 million, reflecting growing confidence that breakthrough science can reach commercial milestones within a fund’s lifecycle.

Notable recipients include a photonic quantum processor startup, a cell‑free protein synthesis platform, and a neuromorphic chip designer. Investors cite improved talent pipelines, clearer regulatory pathways and the strategic imperative of technological sovereignty as key drivers behind the renewed appetite.